

- 5 -

REMARKS

Claims 2-24 were previously pending in the present application and have been cancelled herein. New claims 25-37 have been added. Accordingly, claims 25-37 are currently pending in the application. Support for the newly pending claims can be found in the claims as originally filed and throughout the application. No new matter has been added. For the Examiner's convenience, a copy of the claims that will be pending upon entry of the instant Amendment is attached hereto as Appendix A.

The title and abstract of the disclosure have been amended to more accurately reflect the nature of the invention being claimed. The specification has been amended to add reference to the ATCC deposit of monoclonal antibody, mAb22. A copy of the ATCC Receipts of Deposit for mAb22, as well as mAb32, were submitted in the parent application, Serial No. 08/451,194, along with an executed Declaration For Deposit providing the required assurances by the depositor that all restrictions on the availability of the deposited material will be irrevocably removed upon the granting of a patent.

The foregoing claim cancellations were made solely to expedite the prosecution of the application. Applicants reserve the right to pursue the same or similar subject matter as encompassed by the amended and/or cancelled claims herein or as originally filed in this or a separate application.


- 6 -

CONCLUSION

The present application is now believed to be in condition for allowance.

If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at the number listed below.

Respectfully submitted,


Jane E. Remillard
Registration No. 38,872
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: **December 12, 2000**

APPENDIX A

25. A bispecific molecule comprising an autocrine growth factor specific for a tumor cell and an antibody or antigen binding fragment thereof which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin.

26. The bispecific molecule of claim 25, wherein the tumor cell is a human small-cell lung carcinoma cell.

27. The bispecific molecule of claim 26, wherein the autocrine growth factor binds to the gastrin-releasing peptide receptor of the human small-cell lung carcinoma cell.

28. The bispecific molecule of claim 27, wherein the autocrine growth factor is selected from the group consisting of bombesin and gastrin-releasing peptide and gastrin releasing peptide receptor binding analogues thereof.

29. The bispecific molecule of claim 25, wherein the Fc receptor is selected from the group consisting of FcγRI, FcγRII and FcγRIII.

30. A method of inhibiting proliferation of a tumor cell in a subject, comprising administering to the subject a bispecific molecule comprising (a) an autocrine growth factor specific for the tumor cell and (b) an antibody or an antigen binding fragment thereof which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin.

31. The method of claim 30, wherein the tumor cell is a human small-cell lung carcinoma cell.

- 8 -

32. A method for stimulating an immune response against a tumor cell in a subject comprising administering to the subject a bispecific molecule comprising (a) an autocrine growth factor specific for the tumor cell and (b) an antibody or an antigen binding fragment thereof which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin, wherein the bispecific molecule is administered in a pharmaceutically acceptable carrier.

33. The method of claim 32, wherein the autocrine growth factor is selected from the group consisting of: insulin-like growth factor I, transferrin, vasoactive intestinal peptide, neurotensin, neuromedin B, neurophysin, tumor necrosis factor, transforming growth factor alpha, platelet derived growth factor, the transferin receptor and analogues thereof.

34. The method of claim 32, wherein the autocrine growth factor is selected from the group consisting of bombesin and gastrin releasing peptide or an analogue thereof.

35. The method of claim 30, wherein the autocrine growth factor is selected from the group consisting of bombesin and gastrin releasing peptide or gastrin-releasing peptide receptor binding analogues thereof.

36. The method of claim 32, wherein the Fc receptor is selected from the group consisting of FcγRI, FcγRII and FcγRIII.

37. The method of claim 32, wherein the antibody is selected from the group consisting of: mAb22 produced by the hybridoma having ATCC Accession number HB12147 and mAb32 produced by the hybridoma having ATCC number HB9469.